Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/11/2022* -- Results Q3 2022 -- -0.07 --
08/11/2022 -- Results Q2 2022 -0.06 -0.06 0.00%
05/11/2022 -- Results Q1 2022 -0.05 -0.08 37.50%
03/30/2022 -- Results Q4 2021 -0.07 -0.07 -3.70%
11/12/2021 -- Results Q3 2021 -0.07 -0.09 25.53%
08/12/2021 -- Results Q2 2021 -0.07 -0.12 41.67%
05/13/2021 -- Results Q1 2021 -0.13 -0.10 -36.84%
11/05/2020 -- Results Q3 2020 -0.18 -0.21 12.20%
*Estimated Date/Time

Earnings

Next Report Date 11/11/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/11/2022
Beat/Miss Upgrade
Return Since -1.18%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
URL https://www.savarapharma.com
Investor Relations URL https://savarapharma.com/investors/events-presentations/
HQ State/Province Texas
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 11, 2022 (est.)
Last Earnings Release Aug. 11, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio --
Cash Payout Ratio --
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-24.95%
-79.35%
144.2%
-48.99%
-40.82%
-74.33%
7.83%
35.48%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-8.98%
-17.51%
-57.14%
272.4%
-50.90%
95.31%
-10.93%
102.7%
110.2%
48.92%
-57.23%
-13.04%
-44.44%
36.00%
16.91%
-23.27%
94.26%
122.5%
-84.97%
214.2%
-25.12%
6.35%
26.35%
15.04%
-21.43%
4.97%
71.05%
-88.48%
-96.55%
-8.25%
496.8%
-18.79%
91.48%
As of August 15, 2022.

Profile

Edit
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
URL https://www.savarapharma.com
Investor Relations URL https://savarapharma.com/investors/events-presentations/
HQ State/Province Texas
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Nov. 11, 2022 (est.)
Last Earnings Release Aug. 11, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

No data available
Symbol Dollars Invested % Weight
     
     
     
     
     
     
     
     
     
     

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter SVRA Tweets